Use of Depot Medroxyprogesterone Acetate and Fracture Risk [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2010 Depot medroxyprogesterone acetate (DMPA), which has a high rate of use among teenagers in Europe and the United States, has been associated with impaired bone mineral acquisition during adolescence and accelerated bone loss in later life. Studies on the association between DMPA use and fracture risk are limited.We aimed at evaluating the relationship ...
Meier, Christian +4 more
openaire +6 more sources
The Risk of Infection Human Papilloma Virus Infection in Acceptors of Depot Medroxyprogesterone Acetate Contraceptions [PDF]
Indonesian Journal of Obstetrics and Gynecology, 2018 Objective: Cervical cancer is the second most prevalent cancer in women around the world and the most common cancer in women causing death. This study aims to analyze the connection between infection of human papilloma virus (HPV) 16/18 and cervical ...
Baharuddin Aras +4 more
doaj +2 more sources
Medroxyprogesterone Acetate Plus Metformin to Prevent Persistent Endometrial Hyperplasia
Gynecology Obstetrics & Reproductive Medicine, 2013 OBJECTIVE: To determine the effect of metformin on treatment response in simple endometrial hyperplasia without atypia. STUDY DESIGN: In this study, we identified 134 women with simple endometrial hyperplasia without atypia.
Vakkas Korkmaz +5 more
doaj +1 more source
Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
Open Access Journal of Contraception, 2016 Clarissa Lam,1 Amitasrigowri S Murthy2,3 1New York University School of Medicine, 2Department of Obstetrics and Gynecology, Bellevue Hospital Center, New York University School of Medicine, 3New York University Langone Medical Center, New York,
Lam C, Murthy AS
doaj +1 more source
Depot medroxyprogesterone acetate discontinuation after weight gain in 17-19 year old adolescent girls [PDF]
, 2002 Depot medroxyprogesterone acetate (DMPA) is a long acting progesterone only contraceptive agent. Side effects such as irregular bleeding patterns and weight gain are attributed to discontinuation.
Church, Donna Lea
core +6 more sources
One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH-SY5Y and U-87 MG cancer cells. [PDF]
FEBS Open BioDrugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Kharawatkar A +4 more
europepmc +2 more sources
BMC Women's Health, 2021 Background Subcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive. A trained person can administer it, including women through self-injection.
Ashraf Nabhan +4 more
doaj +1 more source
Depo Medroxyprogesterone Acetate (DMPA): Long-Term Effects on Menstrual Cycle Disorders
Indonesian Journal of Obstetrics and Gynecology, 2023 bjective: To determine the effect of the duration of using Depo Medroxyprogesterone Acetate (DMPA) on the Menstrual Cycle. Methods: This research is an analytical study of 102 patients who used DMPA for less than 1 year and more than 1 year and then ...
Nurhayati Nurhayati +2 more
doaj +1 more source
Frontiers in Physiology, 2020 Preterm premature rupture of membranes is a leading cause of preterm births. Cytokine induced matrix metalloproteinase1 and interleukin 8 production from amnion mesenchymal cells may contribute to fetal membrane weakening and rupture.
William Marinello +2 more
doaj +1 more source
Effect of depot-medroxyprogesterone acetate injections on serum immunoglobulins and complements level [PDF]
المجلة العراقية للصيدلة, 2008 Background: Depot medroxyprogesterone acetate (Depo-Provera) is a highly effective, nondaily hormonal contraceptive option that has been available in the worldwide for 40 years and provides a very high level of contraceptive efficacy. Benefits and risks
Wahda B. Al-Youzbaki
doaj +1 more source